Healthcare Industry News: Abbott
News Release - September 15, 2015
Marathon Pharmaceuticals Names Dr. Jordan Dubow Chief Medical OfficerCHICAGO--(Healthcare Sales & Marketing Network)--Marathon Pharmaceuticals, LLC, a biopharmaceutical company focused on developing treatments for rare neurological and movement disorders, today announced that Dr. Jordan Dubow has joined the company as chief medical officer and vice president of clinical and medical affairs. In his new role, Dr. Dubow will oversee clinical development, medical affairs activities and drug safety for Marathon’s rare disease treatments.
A board-certified neurologist, Dr. Dubow specializes in movement disorders and vascular neurology. Prior to joining Marathon’s executive team, Dr. Dubow acted as vice president of medical affairs at Cynapsus Therapeutics. In that role, he helped design, initiate and oversee pivotal Phase 3 studies, led all medical affairs activities and was the clinical and medical expert for the company’s initial public offering in the United States.
Dr. Dubow also previously worked for Abbott/Abbvie as medical director of neuroscience clinical development. He also has more than 10 years of clinical practice and research experience in both academia and the pharmaceutical industry. He is proficient in both late-stage and early-stage drug development for movement disorders, Alzheimer’s disease, multiple sclerosis and spinal cord injury. Before entering the industry, Dr. Dubow ran a Movement Disorders Center in the Chicago area.
Dr. Dubow earned his Doctor of Medicine degree from Northwestern University’s Feinberg School of Medicine and completed his internal medicine internship, neurology residency and fellowships at the University of California – Los Angeles, Northwestern University and the Weill Cornell Medical College.
“Jordan will be an integral part of Marathon’s effort to improve the lives of patients living with rare neurological and movement disorders,” said Jeff Aronin, CEO of Marathon. “His leadership will help to accelerate our Research and Development efforts and grow our pipeline of rare disease treatments.”
Marathon Pharmaceuticals, LLC is a biopharmaceutical company that develops new treatments for rare diseases with a focus on providing medicine to patients who currently have no treatment options. The company is developing a pipeline of treatments for rare neurological and movement disorders. Marathon is headquartered in Northbrook, Illinois, with offices in Chicago, New Jersey and Washington D.C. For more information, visit www.marathonpharma.com.
Source: Marathon Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.